Abanoquil
Chemical compound
- none
- 2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-6,7-dimethoxyquinolin-4-amine
- 90402-40-7
- 164089
- 143896
Y
- F738MWY53L
- ChEMBL324090 Y
- DTXSID40238163
- Interactive image
- COC1=C(C=C2CN(CCC2=C1)C3=NC4=CC(=C(C=C4C(=C3)N)OC)OC)OC
InChI
- InChI=1S/C22H25N3O4/c1-26-18-7-13-5-6-25(12-14(13)8-19(18)27-2)22-10-16(23)15-9-20(28-3)21(29-4)11-17(15)24-22/h7-11H,5-6,12H2,1-4H3,(H2,23,24)Y
- Key:ANZIISNSHPKVRV-UHFFFAOYSA-NY
Abanoquil (INN) is an α1-adrenergic receptor antagonist.[1]
See also
- Alpha blocker
References
- ^ Tham TC, Guy S, Shanks RG, Harron DW (April 1992). "Dose-dependent alpha 1-adrenoceptor antagonist activity of the anti-arrhythmic drug, abanoquil (UK-52,046), without reduction in blood pressure in man". British Journal of Clinical Pharmacology. 33 (4): 405–9. doi:10.1111/j.1365-2125.1992.tb04059.x. PMC 1381330. PMID 1349492.
- v
- t
- e
(antagonize α-adrenergic
vasoconstriction)
| Central |
| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Peripheral |
|
| Serotonin receptor antagonists | |
|---|---|
| Endothelin receptor antagonists (for PHTooltip Pulmonary hypertension) |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This antihypertensive-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
